Health Condition 1: I509- Heart failure, unspecified Health Condition 2: N189- Chronic kidney disease, unspecified Health Condition 3: E11- Type 2 diabetes mellitus
Conditions
Interventions
None listed
Sponsors
AstraZeneca Pharma India Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. >=18 years old 2. Having type 2 diabetes, CKD and/or HF 3. Providing written informed consent to participate in the study
Exclusion criteria
Exclusion criteria: 1. Having any life-threatening co-morbidity and a life expectancy of less than 1 year 2. Participating in any interventional trial requiring informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Data on real-world management of either/or cardiovascular diseases, T2DM and/or CKD 2. Long-term data collection 3. Truly global data capture 4. Quality KPIs for benchmarking and improving quality of careTimepoint: 12 months | — |
Secondary
| Measure | Time frame |
|---|---|
| To determine risk factors associated with progression of microvascular and macrovascular disease complications, patient outcomes, loss of quality of life, and increased healthcare resource utilization during follow-upTimepoint: 12 Months | — |
Countries
Argentina, Costa Rica, Egypt, Ethiopia, Georgia, Greece, India, Indonesia, Lebanon, Malaysia, Mexico, Philippines, Russian Federation, Saudi Arabia, Singapore, South Africa, Thailand, Ukraine, United Arab Emirates
Contacts
Public ContactMr V V Niranjan Kumar
AstraZeneca Pharma India Ltd.
Outcome results
None listed